Dithranol's Danger: A Cautionary Tale of Accidental Exposure in Children

Atopic dermatitis (AD) is a chronic, inflammatory skin condition common in children, characterized by red, itchy skin. In the described case, a 2.5-year-old girl with existing AD experienced a severe skin reaction after accidental exposure to dithranol. This pre-existing condition made her more susceptible to the irritant effects of dithranol, resulting in an atypical and intensified inflammatory response. The presence of AD complicated the diagnosis, as the symptoms of dithranol-induced contact dermatitis overlapped with AD flare-up symptoms. The young girl had been following a dairy-free diet with standard AD treatments, leading to partial improvement. The sudden flare-up of intense skin lesions prompted the investigation and the discovery of the accidental dithranol exposure.

Dithranol is a medication primarily used to treat psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells, causing thick, scaly patches. It works by slowing down the growth of skin cells and reducing inflammation. However, dithranol can be a potent irritant, especially in children and individuals with sensitive skin conditions like atopic dermatitis. Accidental exposure can cause severe skin reactions, including intense inflammation, redness, and blistering. The case highlights the importance of careful handling and storage of dithranol to prevent such incidents, as the girl's skin showed confluent inflammatory patches with well-defined edges on her cheeks, chest, stomach, back, groins, and upper limbs.

The initial presentation of the child's skin condition, with confluent inflammatory patches and intense itching, baffled doctors, leading them to rule out other conditions like urticaria and erysipelas. The mystery was resolved when the parents revealed the child's grandmother, who was being treated for psoriasis, mistakenly applied dithranol 2% ointment to the child's skin. This information, combined with the physical examination, confirmed the diagnosis of irritant contact dermatitis due to dithranol exposure. Specifically, the doctors considered three conditions: urticaria, erysipelas, and contact dermatitis. Urticaria, characterized by itchy wheals, was absent. Erysipelas was ruled out due to the absence of general symptoms and inflammatory markers. Contact dermatitis was considered when the history of dithranol exposure was established.

Preventing accidental dithranol exposure hinges on several critical measures. First and foremost, proper storage of dithranol is essential; it should be kept securely out of reach of children. Clear communication within households is crucial, particularly if multiple individuals are using different medications. This involves informing all family members about the potential dangers of dithranol and the importance of careful medication management. Moreover, heightened awareness is key: caregivers should always be vigilant about the medications present in the home and their potential risks. Medical errors, including incorrectly administered drugs, are a leading cause of toxicity in children, underscoring the importance of diligence in medication management.

Accidental dithranol exposure can lead to severe skin reactions, including intense inflammation, blistering, and significant discomfort, especially in children and those with skin conditions like atopic dermatitis. This incident underscores the broader issue of adverse drug reactions, which pose a considerable public health challenge. These reactions are associated with high morbidity (illness), significant socioeconomic costs, and potential fatalities. The increasing incidence of drug-induced toxicity, whether through ingestion or skin contact, highlights the importance of ongoing education and vigilance regarding medication safety, proper storage, and the potential risks associated with medications like dithranol, particularly around vulnerable populations such as children.